With one pandemic still raging, J&J bets $780M on a potential flu therapy for the next
As it rolls out the first jabs of its Covid-19 vaccine in the US, J&J already has its eyes on the next pandemic. Now, it’s willing to bet up to $780 million on a new class of drugs that Cidara Therapeutics says could take out all strains of the flu.
Janssen, J&J’s Belgian subsidiary, is plunking down $27 million upfront for access to Cidara’s lead antiviral conjugate CD388, which CEO Jeffrey Stein says has the potential to treat and protect against all flu strains with a single dose. The deal is one example of the next wave of pipeline work being established as the US begins to get its hands around the current pandemic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.